Related Experiment Video
Updated: Jul 6, 2026
08:16
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
[Methods for diagnosing seronegative myasthenia gravis].
T Blanco-Hernández1, A Navarré-Gimeno, A Brocalero-Camacho
1Servicio de Neurología, Sección de Neurofisiología, Consorcio Hospital General Universitario, Avda, Tres Cruces, s/n, E-46014 Valencia, España. blanco_tri@gva.es
Revista De Neurologia
|March 28, 2008
Summary
Diagnosing MuSK-antibody positive myasthenia gravis involves checking for muscle-specific kinase (MuSK) antibodies and neurophysiological changes. Early diagnosis and monitoring are crucial for managing this severe form of the disease.
Area of Science:
- Neurology
- Immunology
Context:
- Seronegative myasthenia gravis (MG) presents a diagnostic challenge due to negative acetylcholine-receptor antibodies.
- Muscle-specific receptor tyrosine kinase (MuSK) antibodies identify a distinct subgroup of generalized MG patients with unique characteristics.
Purpose:
- To outline the diagnostic criteria for MuSK-antibody positive MG.
- To highlight the clinical and neurophysiological peculiarities of this MG subtype.
- To emphasize the importance of antibody testing and neurophysiological assessment for diagnosis and management.
Summary:
- Diagnosis requires muscle weakness, fatigability, positive anti-MuSK antibodies, and neuromuscular junction neurophysiological alterations.
- MuSK-antibody positive MG is typically severe, with a poorer prognosis, rapid onset, and predominant facial, bulbar, and respiratory muscle involvement.
- Single-fiber electromyography (SFEMG) jitter assessment is vital for early diagnosis and objective monitoring of disease progression and treatment response.
Impact:
- Facilitates earlier and more accurate diagnosis of MuSK-antibody positive myasthenia gravis.
- Enables objective evaluation of treatment efficacy and disease progression.
- Improves patient outcomes by guiding appropriate management strategies for this severe MG subtype.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...